Desferrioxamine, Legalon
Phase 1Small molecule
Desferrioxamine, Legalon is one of 10 small molecule programs targeting Beta-Thalassemia Major. It is currently in Phase 1.
1
Indications
1
Total Trials
0
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Beta-Thalassemia Major
#DrugCompanyPhaseTrials
1Jakafi
IncyteApproved
Exjade
NovartisApproved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Cecon
MMcGuff Pharmaceuticals, Inc.
Approved
Winrevair
Merck & Co.Phase 2
Ferriprox
Chiesi Farmaceutici S.p.A.Phase 2
Legalon
BBukwang Pharmaceutical
Phase 1
Alpha Tocopherol
TThammasat University
Preclinical
Desferrioxamine, Legalon
SShiraz University of Medical Sciences
Phase 1
Mozobil
NNational Institute of Allergy and Infectious Diseases (NIAID)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Desferrioxamine, Legalon. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details